Can new scans predict chemo success in Triple-Negative breast cancer?
NCT ID NCT02744053
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 33 times
Summary
This early-phase trial is testing whether two advanced imaging techniques—DCE-MRI and molecular breast imaging (MBI)—can accurately assess how triple-negative breast cancer tumors respond to chemotherapy. About 96 patients will undergo these scans before, during, and after treatment. The goal is to see if these imaging methods can predict which patients are responding well, potentially helping doctors tailor treatment earlier.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson League City
Nassau Bay, Texas, 77058, United States
-
MD Anderson in Katy
Houston, Texas, 77094, United States
-
MD Anderson in Sugar Land
Sugar Land, Texas, 77478, United States
-
MD Anderson in The Woodlands
The Woodlands, Texas, 77384, United States
-
Memorial Hermann Memorial City Medical Center
Houston, Texas, 77024, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium Tc-99m Sestamibi (imaging tracer)
What this could lead to
If successful, this could help doctors predict which triple-negative breast cancer patients are responding to chemotherapy, potentially guiding more personalized treatment.
What could go wrong
This is a very early (phase 1) imaging study with only 96 participants, so results may not apply broadly. It focuses on measuring response, not on improving outcomes directly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.